New drug AMN1126 passes first safety check in healthy women
NCT ID NCT06467201
First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This early-stage study tested a single dose of the experimental drug AMN1126 in 18 healthy postmenopausal women to see if it is safe and how the body processes it. The goal was not to treat any disease, but to gather initial safety information and measure drug levels in the blood. No treatment benefits were expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY POSTMENOPAUSAL WOMEN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Pharma CR
Miami, Florida, 33147, United States
-
Health1 Superspeciality Hospital
Ahmedabad, Gujarat, 380058, India
Conditions
Explore the condition pages connected to this study.